ArticleArchives of gynecology and obstetrics2026
Tumor biology, treatment patterns, and recurrence in breast cancer patients aged 70-79 vs ≥ 80 years: a large-scale registry analysis.
Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWith increasing life expectancy, breast cancer (BC) in elderly women is rising, yet patients over 80 remain underrepresented in clinical trials. Understanding differences in the age groups is essential to avoid over- and undertreatment. This analysis investigates age-specific tumor characteristics, treatment patterns and outcomes in women aged 70-79 versus ≥ 80 years.
methodsThis population-based analysis included BC patients treated at LMU Breast Center and Munich Red Cross Hospital between 2004 and 2015. Clinical data of 2699 women aged 70-79 and those ≥ 80 were compared to assess differences in tumor biology, treatment approaches and time to metastasis.
resultsBreast-conserving surgery rates remained stable over time, while sentinel lymph node biopsy use increased in both age groups. Patients aged ≥ 80 more frequently presented with larger tumors, underwent mastectomy, and received less systemic or axillary treatment, despite similarly high hormone-receptor positivity. Chemotherapy use peaked in 2009 and declined thereafter, whereas endocrine therapy (ET) increased steadily. Patients ≥ 80 received chemotherapy less often and more frequently ET alone. Across all biological subtypes, patients ≥ 80 were associated with higher rates of distant metastasis compared with those aged 70-79 years.
conclusionClinical and biological differences between women aged 70-79 and those ≥ 80 underscore the need for age-adapted, individualized BC management. Treatment decisions should carefully balance expected benefit against comorbidity burden and functional status. Refining age-specific treatment strategies may help to improve outcomes and quality of life, although this analysis cannot determine the effects of specific strategies in this growing patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.